Summary
As the principal effector cell population of the innate immune system, natural killer (NK) cells may make critical contributions to natural, immune-mediated control of HIV-1 replication. Using genome-wide assessments of activating and inhibitory chromatin features, we demonstrate here that cytotoxic NK (cNK) cells from elite controllers (ECs) display elevated activating histone modifications at the interleukin 2 (IL-2)/IL-15 receptor β chain and the BCL2 gene loci. These histone changes translate into increased responsiveness of cNK cells to paracrine IL-15 secretion, which coincides with higher levels of IL-15 transcription by myeloid dendritic cells in ECs. The distinct immune crosstalk between these innate immune cell populations results in improved IL-15-dependent cNK cell survival and cytotoxicity, paired with a metabolic profile biased toward IL-15-mediated glycolytic activities. Together, these results suggest that cNK cells from ECs display a programmed IL-15 response signature and support the emerging role of innate immune pathways in natural, drug-free control of HIV-1.
Keywords: NK cells, HIV infection, elite controllers, trained innate immunity, IL-15, chromatin modifications, cytotoxicity, metabolism
Graphical abstract
Highlights
-
•
Enhanced activating histone marks on IL2Rβ and BCL2 genes in cNK cells from ECs
-
•
Elevated levels of IL-15 transcription in myeloid DCs from ECs
-
•
Improved survival and increased cytotoxicity in cNK cells after IL-15 stimulation
-
•
Increased glycolytic activities in cNK cells from ECs after IL-15 stimulation
Hartana et al. observed elevated IL-15 responsiveness of cNK cells from HIV-1 elite controllers, paired with increased levels of IL-15 transcription in mDCs. These results suggest that immune crosstalk between mDCs and cNK cells results in distinct IL-15 response signatures and may contribute to drug-free control of HIV-1 replication.
Introduction
A cure for HIV-1 infection, previously considered elusive, has been observed in four people living with HIV (PLWH) with leukemia undergoing transplantation with CCR5Δ32-expressing hematopoietic stem cells.1,2,3,4 Provocatively, the absence of intact HIV-1 proviruses in billions of peripheral blood mononuclear cells (PBMCs) has also been described in two PLWH without hematopoietic stem cell transplantation, suggesting that a “virological cure” of HIV-1 disease can emerge through natural, immune-mediated mechanisms.5,6 Drug-free, “elite” control of plasma HIV-1 viremia to undetectable levels, frequently considered a “functional” cure of HIV-1-infection, occurs in approximately 0.5%–1% of PLWH; however, small reservoirs of infected cells are readily detectable in these individuals.7 Although host immune factors are widely considered as the underlying etiology of elite control,8,9 insight into the specific underlying immune mechanisms remains limited. Recent studies suggest a bias of proviral HIV-1 integration sites toward heterochromatin chromosomal locations in elite controllers (ECs), best explained by immune selection pressure, promoting the elimination of proviruses in accessible chromatin.5 In contrast, proviruses integrated in non-accessible genomic regions and displaying a state of deep latency, presumably with a more limited ability to drive viral rebound, seem to persist long term in EC.5
HIV-1-specific CD8+ T cells are considered the most likely drivers of such immunological selection processes10,11,12,13,14 based on strong immunogenetic associations between polymorphisms within the HLA class I binding pocket and natural HIV-1 control.10 However, a role for innate immune mechanisms, in particular natural killer (NK) cells, in HIV-1 immune control has also been proposed.15 Like CD8+ T cells,16,17,18 NK cells undergo rapid and dynamic changes in the early phase of HIV-1 infection, and they can mount direct cytotoxic effects against HIV-1-infected cells that do not depend on HLA class I restriction and are less prone to viral mutational escape.19,20,21 Furthermore, early data suggested that the frequency of cytotoxic NK cells is almost two times higher in HIV-1 ECs compared to non-controller PLWH22 and that NK cells from ECs may have distinct phenotypic profiles.23 Moreover, NK cells can effectively suppress viral replication in in vitro viral inhibition assays24,25,26,27,28,29 independently of CD8+ T cells.30,31 Several subsets of NK cells are distinguished based on phenotypic and functional considerations. CD56dim CD16+ cytotoxic NK (cNK) cells, which are investigated in this study, represent the most dominant subset of NK cells and have direct cytotoxic capacities.19 In contrast, CD56bright CD16− NK cells are known for their ability to produce inflammatory cytokines, providing paracrine activation signals to other immune cells.19 While some studies suggested the evolution of memory NK cell responses, predominantly in animal models,32,33,34,35 definitive evidence for NK memory cells in humans is currently lacking. Yet, several studies demonstrated that innate immune cells can be “trained.”36,37
The concept of “trained innate immunity” suggests that innate immune cells are poised by an initial viral infection to respond more potently upon secondary infections, in a pattern that is reminiscent of a memory-cell-like behavior.38 Trained innate immune cells can frequently be distinguished by distinct epigenetic profiles, which we define as histone modifications and other chromatin characteristics that impact gene transcription without changing the DNA sequence; frequently, epigenetic changes can prominently shape the cellular metabolism and functions of these cells.17,36,39,40 Our recent work suggests that myeloid dendritic cells (mDCs) from HIV-1 ECs have improved immunometabolic properties, likely as a result of epigenetic changes in gene-locus-specific histone modifications.41 These results raised the possibility that in ECs, trained innate immune responses can make critical contributions to immunological selection pressure against infected CD4+ T cells. In this study, we hypothesized that NK cell responses with features of “trained immunity” contribute to HIV-1 immune control in ECs. Based on a comprehensive characterization of epigenetic, transcriptomic, and metabolic profiles of CD56dim CD16+ cNK cells from a well-characterized cohort of ECs, we demonstrated that NK cells from such individuals displayed distinct epigenetic and transcriptional features, which are likely to influence their survival, cytotoxic capacities, metabolic activities, and susceptibility to interleukin-15 (IL-15)-mediated immune crosstalk with DCs.
Results
Distinct epigenomic profiles of CD56dim CD16+ cNK cells from ECs
To evaluate NK cell profiles from ECs, we initially performed an epigenetic analysis of sorted primary NK cells from 5 ECs relative to PLWH treated with antiretroviral therapy (ART) (ARTs; n = 5) and people without HIV (HIVNs; n = 5) (Figure 1A). Epigenomic analysis was performed using the cleavage under target and release using nuclease sequencing (CUT&RUN-Seq) assay,42 allowing for a genome-wide identification of DNA segments binding to defined activating (H3K27ac and H3K4me3) or inhibitory (H3K27me3) histone marks. Given that epigenetic and transcriptional features may vary within individual NK cell subsets, we restricted our experiments to sorted CD56dim CD16+ cNK cells, which possess strong cytotoxic activities and typically represent the most prevalent NK cell subset in adults.19 As an additional reference cell population, we sorted CD56bright CD16− NK cells, frequently characterized by secretions of inflammatory cytokines19 (Figure S1A).
We observed that the epigenomic profiles of activating H3K27ac and H3K4me3 marks in CD56dim CD16+ cNK cells from ECs showed a discrete spatial positioning relative to the other two cohorts on linear discriminant analysis (LDA) plots (Figure 1B); in contrast, no such differences were observed for epigenetic profiles related to the inhibitory histone mark H3K27me3. Corresponding to this global analysis, we noted a signature of genes with significant enrichment or de-enrichment for H3K27ac and H3K4me3 at the respective genomic locations of cNK cells from ECs relative to the reference cell populations; however, genes with differential H3K27me3 marks were less obvious in ECs compared to people without HIV (Figure 1C; Table S1). Moreover, Ingenuity Pathway Analysis (IPA) suggested that genes with enhanced activating histone modifications in ECs were functionally involved in the regulation of immune activity, oncogenesis, and cell metabolism (Figures S2A–S2F). In contrast to CD56dim CD16+ cNK cells, epigenetic differences between ECs and reference cohorts of PLWH on ART or people without HIV were less apparent within in the CD56bright CD16− NK cell subset (Figure S1B). For this reason, our subsequent analysis focused on a further exploration of the CD56dim CD16+ cNK cell population.
Transcriptional and epigenetic activation of the IL-2-Rβ chain in cNK cells from ECs
We subsequently evaluated the associations between the epigenetic profiles and transcriptional signatures. For this purpose, we performed RNA-Seq on autologous sorted CD56dim CD16+ cNK cells from our study participants. Overall, we noted a number of genes that were differentially expressed in ECs relative to PLWH on ART and people without HIV (Figures 2A and 2B). A computational IPA predicted that this differential gene expression signature in cNK cells from ECs (Figure 2C) translated into activation of pathways related to the crosstalk between DCs and NK cells, NK cell signaling, metabolic regulation, and IL-15-dependent immune activation (Figures 2D and 2E).
To further investigate these transcriptional changes in the context of the epigenetic data, we focused on the gene encoding for the β chain (CD122) of the IL-2 and IL-15 receptor complex. CD122 (IL-2-Rβ) can form a heterodimer receptor complex for both IL-2 and IL-15 that is selectively expressed on cNK cells and CD8+ T cells.43 We observed that primary cNK cells from ECs had a higher enrichment of H3K27ac marks on the IL2RB gene region compared to PLWH on ART and people without HIV; higher H3K4me3 mark enrichments were also observed in ECs but reached levels of statistical significance only in comparison to people without HIV (Figures 2F, 3A, and S3A; Tables S2 and S3). Inhibitory H3K27me3 histone modifications showed no differences at the IL2RB locus between the three study cohorts. Notably, the enrichment of activating histone marks was seen in the promoter and enhancer regions of the IL2RB gene, which are essential for gene transcription (Figures 3A and 3B). Enhanced activating epigenetic marks on the IL2RB gene in ECs were associated with elevated transcriptional activity, specifically in comparison to people without HIV (Figures 3A and 3B). Consequently, an upregulation of the IL-2-Rβ surface protein expression was seen in primary, steady-state cNK cells from ECs compared to PLWH on ART (p = 0.0484) and people without HIV (p = 0.0018) (Figures 3C and S3B). Together, these findings suggest an altered epigenetic and transcriptional program in cNK cells from ECs that involves increased signaling via the IL-2-Rβ chain.
Increased transcriptional propensity for paracrine IL-15 secretion in ECs
IL-2 and IL-15 both act as physiological ligands for the receptor complex formed by the IL-2 receptor β chain on NK cells43; however, IL-15 provides more potent signals for NK cell development, expansion, and survival compared to IL-2.44,45,46,47 Additionally, IL-15 seems to have a higher affinity to its receptor complex compared to IL-2.45 Using RNA sequencing (RNA-seq) data from defined sorted immune cell subsets from ECs,48 we noted that the expression of the IL15 mRNA was significantly higher in mDCs from ECs compared to PLWH on ART (p < 0.0001) and people without HIV (p = 0.0186) (Figure 3D); a similar, although less pronounced, finding was made for CD4+ T cells but not for B cells or monocytes (Figure S3D). Following TLR3 stimulation using poly(I:C) to activate mDCs, the expression of IL15 mRNA in mDCs from ECs increased profoundly and again markedly exceeded corresponding levels in mDCs from PLWH on ART (p = 0.0001) or people without HIV-1 (p = 0.0069) (Figure 3E). In contrast, IL2 mRNA expression was not different in any of the immune cell subsets from any of our study cohorts (Figures 3E and S3C). Thus, the elevated epigenetic and transcriptional activation of the IL-2-Rβ chain in cNK cells from ECs seems to converge with an increased propensity of autologous mDCs (and, to a lesser extent, of CD4+ T cells) for paracrine IL-15 secretion. Together, these results suggest that improved IL-15 receptor/ligand interactions may underlie distinct cNK cell functionalities in ECs.
cNK cells from ECs are epigenetically poised for improved BCL-2 upregulation and increased cytotoxicity after IL-15 stimulation
To investigate the responses of NK cells to IL-15 stimulation, we performed transcriptomic profiling of NK cells from 4 people without HIV using RNA-seq. Consistent with the results of cNK cells analyzed directly ex vivo (Figures 2D and 2E), we noticed that the exposure to exogenous IL-15 resulted in differential expression of genes (Figure 4A) involved in pathways related to the crosstalk between DCs and NK cells, NK cell signaling, and IL-15-dependent immune activation (Figures 4B and 4C). Notably, the gene encoding for the antiapoptosis molecule BCL-2 was among the genes most strongly upregulated in IL-15-stimulated NK cells (Figures 4D and S4A). Moreover, predicted canonical pathways and upstream regulators responding to IL-15 stimulation frequently included the BCL2 gene (Figures 4B and 4C). Other genes with notable upregulation following IL-15 stimulation encoded for the IL-2 receptor α chain and for the NK cell activation marker CD69 (Figures 4B–4D and S4A).
Notably, we observed an enrichment of the activating H3K27ac and H3K4me3 histone marks at the BCL2 gene in cNK cells from ECs analyzed directly ex vivo compared to PLWH on ART and people without HIV (Figures 4E and S4B). These activating histone marks populated the promoter- and enhancer-adjacent regions of BCL2 gene (Figures 4E and 4F). In contrast, expression of BCL2 in primary cNK cells from ECs was not elevated at baseline on the RNA or protein level (Figure S4C), suggesting that the activating histone marks at the BCL2 gene locus in ex-vivo-isolated cNK cells are not directly translating into transcriptional activation but predispose cNK cells to increased upregulation of BCL-2 in response to IL-15 stimulation. To further explore this, we measured the intracellular expression of the BCL-2 protein following IL-15 stimulation in our study cohorts using flow cytometry. After IL-15 stimulation, intracellular BCL-2 expression was significantly higher in activated CD69+ cNK cells from ECs in comparison to the reference cohorts (ECs vs. ARTs p = 0.011; ECs vs. HIVNs p = 0.001) (Figure 4G). In addition, the expression changes of BCL-2 in CD69+ cNK cells after IL-15 stimulation were positively associated with the surface expression of the IL-2-Rβ chain at baseline (Figure 4H), suggesting that the elevated expression of the IL-15 receptor may contribute to a higher responsiveness to IL-15 stimulation, which then translates into elevated BCL-2 expression. Together, these findings suggest that elevated expression of the IL-2-Rβ chain synergizes with increased paracrine IL-15 secretion to enhance BCL-2 expression in epigenetically poised cNK cells. Such a distinct interplay between IL-15, the IL-2-Rβ chain, and the BCL-2 at the transcriptional and epigenetic levels is likely to translate into an improved survival of cNK cells from ECs.
Supporting this concept on a functional level, we observed that the proportion of cNK cells from ECs that remained viable over 24 h of in vitro culture with exogenous IL-15 was significantly higher compared to cNK cells from PLWH on ART and people without HIV (Figure S4D). We also noted that treatment with venetoclax, a BCL-2 inhibitor, resulted in a notable reduction in the proportion of CD69-, Ki-67-, and IL-2-Rα-expressing cNK cells, consistent with the important role of BCL-2 for maintaining the viability of cNK cells (Figure 4J). Interestingly, functional assays revealed that IL-15-stimulated cNK cells from ECs display significantly higher cytotoxic activities compared to people without HIV; there was also a trend for elevated cytotoxicity of IL-15-stimulated cNK cells from EC relative to PLWH on ART (Figure 4I). These results suggest that a higher responsiveness to IL-15 can translate into improved NK-cell-mediated killing of target cells. Together, these experiments support our hypothesis that the described epigenetic changes in cNK cells from ECs are functionally relevant for maintaining cell survival and cytotoxic activities.
NK cells from ECs show increased glycolytic activities
Epigenetic changes in immune cells, specifically in the context of “trained immunity,” are frequently associated with altered metabolic programs.38,49 To further investigate functional changes in NK cells from ECs after IL-15 stimulation, we therefore evaluated their metabolic profiles, in particular their glycolytic activities. For this purpose, we stimulated NK cells from these cohorts with IL-15, followed by an evaluation of the extracellular acidification rate (ECAR), using the Seahorse technology.50 In response to IL-15 stimulation, a general increase of the ECAR was seen compared to baseline control (medium) (Figure 5A). Notably, we observed that glycolysis, glycolytic capacity, and glycolytic reserve were significantly higher in NK cells from ECs compared to PLWH on ART and people without HIV following IL-15 stimulation (Figures 5B–5D). These data suggest that NK cells from ECs display a distinct functional metabolic profile characterized by increased glycolytic activities following IL-15 stimulation.
Discussion
Drug-free maintenance of undetectable plasma HIV-1 viral loads is best exemplified by ECs, and these individuals are frequently considered a model for a functional cure of HIV-1 infection. Innate immune activity may play an important role in promoting such a remarkable disease outcome, although their contribution relative to adaptive HIV-1-specific T cell-mediated immune responses remains an area of active investigation. Here, we demonstrated distinct epigenomic, transcriptomic, and metabolic profiles of CD56dim CD16+ cNK cells from ECs. In particular, we found that primary cNK cells from ECs displayed higher levels of activating epigenetic chromatin features at the IL2RB gene locus, which was associated with a higher expression of the β chain of IL-15 receptor complex (IL-2-Rβ). Correspondingly, IL-15 transcription was strongly upregulated in mDCs from ECs, suggesting that the elevated expression of the IL-15 receptor on NK cells and enhanced paracrine IL-15 secretion in mDCs synergize in maintaining an enhanced IL-15 response signature in cNK cells from ECs. In line with these observations, we noted that IL-15 stimulation strongly enhanced BCL-2 protein expression and survival in cNK cells from ECs and augmented their cytotoxic properties and their functional glycolytic metabolic activities.
In previous studies, host characteristics of ECs were frequently evaluated using transcriptomic studies51,52,53,54 or genome-wide association studies (GWASs),10 while epigenetic investigations of immune cells, including NK cells, remain limited. Although epigenetic changes may in many cases not directly associate with gene expression changes at the transcriptional or proteomic level, they frequently can influence host behavior in response to immunological or microbiological challenges and contribute to a state of heightened innate immune activity frequently referred to as “trained immunity.”38 In our study, we observed at least two epigenetic alterations in cNK cells from ECs that likely influence their functional responsiveness and activity. We noted increased activating histone modifications at promoter and enhancer regions of the IL-2/IL-15 receptor β chain locus and at the BCL2 gene locus. Both of these epigenetic changes seem functionally interconnected and may translate into increased functionality and resilience. Epigenetic and transcriptional activation of the IL-15 receptor can increase cell responsiveness to IL-15; IL-15 stimulation can then capitalize on epigenetically programmed BCL-2 activation to augment NK cell survival via BCL-2 upregulation. Together, these results support the hypothesis that epigenetic changes may predispose cNK cells to improved biological activity under conditions of stress and immune stimulation. The exact mechanisms that contribute to the evolution of trained immunity in cNK cells from ECs remains unknown at present but may involve prior pathogen exposure, specific immunogenetic alterations, or a fine-tuned cytokine milieu.55 Future efforts may allow for delineating epigenetic changes of cNK cells in much greater detail and may soon permit evaluation of the epigenetic and transcriptional changes of cNK cells at single-cell resolution.
Our data suggest qualitatively distinct cNK cell responses in ECs, primarily characterized by increased IL-15-dependent functionality that was paired with an increased IL-15 transcription in mDCs. We have previously shown that mDCs from ECs also present features of trained immunity,41 suggesting that innate immune activity in ECs is more broadly influenced by trained immune features. Of note, the higher constitutive levels of IL-15 in mDCs reported in this study could also be one functional consequence of the epigenetic remodeling of these cells, although this remains conjectural at the current time; in fact, our prior study failed to demonstrate significant upregulation of activating histone modifications at the IL-15 gene locus. Interestingly, IL-15 is currently being evaluated as an immune-modulatory agent in multiple clinical studies designed to increase drug-free control of HIV-1 infection. In humans, the pharmacological administration of the IL-15 super agonist N-803 resulted in an expansion of NK cell frequencies and activation, along with a modest reduction in inducible HIV-1 reservoir cells.56 Moreover, in simian immunodeficiency virus (SIV)-infected rhesus macaques, N-803 administration induced activation and trafficking of NK cells to the B cell follicles in lymph nodes,57 while inhibition of IL-15 using neutralizing IL-15 antibodies in SIV-infected rhesus macaques profoundly depleted NK cell numbers in peripheral blood and tissues.58 Finally, partial control of SIV after vaccination with a cytomegalovirus (CMV)-vectored immunogen was associated with a transcriptional signature dominated by IL-15 as an upstream regulator,59 a notion that corresponds well to the epigenetically programmed, IL-15-dependent signature of cNK cell regulation in ECs described here. One limitation of our current study was that IL-15 plasma levels were not directly assessed, given that the physiological half-life of IL-15 is extremely short,60 rendering it difficult to correctly measure IL-15 plasma concentrations. Moreover, we only analyzed the effects of IL-15 on NK cells in the peripheral blood, not in the lymph node samples, where IL-15 immune effects on NK cells may be most visible; therefore, future studies to investigate the role of IL-15 on NK cell trafficking to the lymph nodes in ECs will be informative.
An expanding set of data suggests that NK cells can contribute to immune defense against HIV-1 in controllers and post-treatment controllers,15 although their antiviral functions are less clearly understood compared to HIV-1-specific T cells. Some studies suggested that in ECs, the frequencies of CD56dim cNK cells are two times higher, paired with lower expression of inhibitory markers TIGIT and LAG3.22 Other studies suggested that NK cells from ECs have higher expression levels of the activating receptor NKG2D and the cytotoxicity-associated marker CD57 and a lower expression of the inhibitory receptor NKG2A relative to NK cells from individuals without HIV.26 Generally, cytotoxic activities of NK cells are regulated by a specific set of activating and inhibitory receptors expressed on the NK cell surface and their corresponding ligands on target cells.61,62 Previous studies demonstrated that education of NK cells via KIRs or NKG2A increases their cytotoxic properties63,64; however, their true cytotoxic activity against HIV-1-infected cells is difficult to assess, given that the physiological expression of NK cell ligands on virally-infected, participant-derived CD4 T cells is not known. However, recent technical advances in single-cell proteogenomic profiling of HIV-1-infected cells may soon allow for jointly characterizing the cytotoxic activities of NK cells and the corresponding susceptibility of infected target cells to NK-cell-mediated killing.65 Such novel technologies will better permit determining whether the distinct epigenetic and transcriptional features of cNK cells from ECs translate into an improved functional effector cell profile.
In summary, the work presented here suggests that cNK cells from ECs display distinct epigenetic and transcriptional features that promote improved susceptibility to IL-15, which then translate into elevated IL-15-dependent survival and enhanced cytotoxic and metabolic activities. Such an altered functional state appears to resemble a condition of “trained innate immunity.” Together with prior studies demonstrating features of trained immunity in mDCs from ECs,66 our data suggest that altered epigenetic and transcriptional programs in innate immune cells may represent an important aspect of antiviral immune defense in ECs. Continued progress in understanding and unraveling the fascinating components of antiviral immune activity in these specific individuals may lead to actionable interventions designed to induce natural control of HIV-1 in larger numbers of individuals.
Limitations of the study
We acknowledge that the number of study subjects reported in this article is relatively small; however, genome-wide epigenetic profiling can, at the current stage of technology development, not be conducted for larger numbers of study participants. Moreover, our data also failed to demonstrate direct mechanistic linkages between metabolic activities and cytotoxic activities of NK cells; such investigations will require dedicated future mechanistic evaluations.
STAR★Methods
Key resources table
REAGENT or RESOURCE | SOURCE | IDENTIFIER |
---|---|---|
Antibodies | ||
Anti-CD3 PE-Cy5 | BioLegend | AB_314046 |
Anti-CD3 APC-Cy7 | BioLegend | B_314054 |
Anti-CD3 AF700 | BioLegend | AB_493739 |
Anti-CD14 PE-Cy5 | BioLegend | AB_2860767 |
Anti-CD14 APC-Cy7 | BioLegend | AB_830693 |
Anti-CD14 AF700 | BioLegend | AB_830687 |
Anti-CD19 PE-Cy5 | BioLegend | AB_314240 |
Anti-CD19 APC-Cy7 | BioLegend | AB_314248 |
Anti-CD19 AF700 | BioLegend | AB_493751 |
Anti-CD56 BV570 | BioLegend | AB_2563837 |
Anti-CD56 BV711 | BioLegend | AB_2562417 |
Anti-CD56 BV650 | BioLegend | AB_2563838 |
Anti-CD16 BUV395 | BD Biosciences | Cat #: 563785 |
Anti-CD16 PE | BioLegend | AB_314208 |
Anti-CD122 (IL-2Rβ) BV786 | BD Biosciences | Cat #: 743118 |
Anti-CD69 BUV805 | BD Biosciences | Cat #: 748763 |
Anti-BCL2 PE | BioLegend | AB_2563282 |
Anti-Perforin PE-Cy7 | BioLegend | AB_2571973 |
Anti-Granzyme B BV510 | BD Biosciences | Cat #: 563388 |
Anti-Ki-67 BUV737 | BD Biosciences | Cat #: 567130 |
Anti-CD25 (IL-2Rα) BUV563 | BD Biosciences | Cat #: 612918 |
Anti-CD94 BB790 | BD Biosciences | Cat #: 624296 |
Anti-NKp30 BB700 | BD Biosciences | Cat #: 745937 |
Anti-Tim-3 BB660 | BD Biosciences | Cat #: 624295 |
Anti-LAG3 BB630 | BD Biosciences | Cat #: 624294 |
Anti-NKG7 FITC | LSBio | Cat #: LS-C377334-100 |
Anti-CD57 PE-Cy7 | BioLegend | AB_2632689 |
Anti-NKG2D PE/Dazzle594 | BioLegend | AB_2687173 |
Anti-CD158 (KIR2DL1) PE | BioLegend | AB_2130374 |
Anti-Siglec7 APC-Fire 750 | BioLegend | AB_2814244 |
Anti-CD158e1 (KIR3DL1) AF700 | BioLegend | AB_2130824 |
Anti-CD158d (KIR2DL4) APC | BioLegend | AB_2130691 |
Anti-DNAM-1 BV711 | BioLegend | AB_2728304 |
Anti-CD161 BV650 | BD Biosciences | Cat #: 563864 |
Anti-NKG2C BV480 | BD Biosciences | Cat #: 748168 |
Anti-NKG2A BV421 | BD Biosciences | Cat #: 747924 |
Anti-PD-1 BUV737 | BD Biosciences | Cat #: 612791 |
Anti-CD158b (KIR2DL2) BUV661 | BD Biosciences | Cat #: 750777 |
Anti-GM-CSF PerCp-Cy5.5 | BioLegend | AB_11147946 |
Anti-BCL11b FITC | Abcam | AB_10973033 |
Anti-EOMES PE-efluor 610 | eBioscience | Cat #: 61-4877-42 |
Anti-Tbet PE | BioLegend | AB_2200542 |
Anti-IFNγ AF647 | BioLegend | AB_493031 |
Anti-CD107a BV786 | BD Biosciences | Cat #: 563869 |
Anti-IL-2 BV650 | BioLegend | AB_2563878 |
Anti-H3K27ac | Cell Signaling Technology | AB_10949503 |
Anti-H3K27me | Cell Signaling Technology | AB_2616029 |
Anti-H3K4me3 | Cell Signaling Technology | AB_2616028 |
Anti-rabbit IgG | Antibodies-online | AB_10775589 |
Biological samples | ||
PBMC samples from study participants living with HIV-1 and HIV-1 negative individuals. | Ragon Institute Biobank and MGH Blood Bank | ragon.partners.org |
Chemicals, peptides, and recombinant proteins | ||
Concanavalin-A coated magnetic beads | Bangs Labooratory | Cat #: BP531 |
Digitonin | Millipore | Cat #: 300410 |
CUTANA™ pAG-MNase for ChIC/CUT&RUN 50 Rxns | Epicypher | Cat #: 15-1016 |
IL-15 | Miltenyi | Cat #: 130-095-764 |
Brefeldin A | BioLegend | Cat #: 420601 |
Monensin | BD Biosciences | Cat #: 554724 |
Venetoclax | Selleckchem | Cat #: S8048 |
Poly(I:C) | Invivogen | Cat #: tlrl-pic-5 |
LIVE/DEAD™ Fixable Blue Dead Cell Stain Kit | Thermo Fisher Scientific | Cat #: L23105 |
FcR Blocking Reagent, human | Miltenyi | Cat #: 130-059-901 |
FOXP3 / Transcription factor staining buffer set | Invitrogen/eBioscience | Cat #: 00-5523-00 |
Paraformaldehyde solution 4% in PBS | Affymetrix | Cat #: 4243418 |
Distilled, deionized or RNAse-free H2O | Promega | Cat #: P1197 |
Manganese Chloride (MnCl2) | Sigma Aldrich | Cat #: 203734-5g |
Calcium Chloride (CaCl2) | Fisher Scientific | Cat #: BP510-100g |
Potassium Chloride (KCl) | Sigma Aldrich | Cat #: P3911-25g |
Hydroxyethyl piperazineethanesulfonic acid | Sigma Aldrich | Cat #: H3375-25g |
Sodium chloride (NaCl) | Sigma Aldrich | Cat #: S5150-1L |
Ethylenediaminetetraacetic acid (EDTA) | Sigma Aldrich | Cat #: E7889 |
Ethylene glycol-bis(β-aminoethyl ether)-N,N,N,N-tetraacetic acid (EGTA) | Sigma Aldrich | Cat #: E3889-10G |
Roche Complete Protease Inhibitor EDTA-Free tablets | Sigma Aldrich | Cat #: 11873580001 |
RNase A, DNase and protease-free (10 mg/ml) | Thermo Fisher Scientific | Cat #: EN0531 |
Agencourt AMPure XP magnetic beads | Beckman Coulter | Cat #: A63880 |
Sodium dodecyl sulfate (SDS) | Sigma Aldrich | Cat #: L4509-25G |
Proteinase K | Thermo Fisher Scientific | Cat #: EO0491 |
Phenol-chloroform-isoamyl alcohol | Thermo Fisher Scientific | Cat #: 15593031 |
Chloroform | Sigma Aldrich | Cat #: 366919-1L |
1 M Tris-HCl pH 8.0 | Fisher Scientific | Cat #: AAJ22638AP |
20 mg/ml Glycogen | Sigma Aldrich | Cat #: 10901393001 |
Agencourt RNAClean XP | Beckman Coulter | Cat #: A63987 |
SUPERase⋅ In™ RNase Inhibitor (20 U/μL) | Life Technologies | Cat #: AM2696 |
SuperScript™ III Reverse Transcriptase | Life Technologies | Cat #: 18080085 |
dNTP Mix (10 mM ea) | Life Technologies | Cat #: 18427088 |
Ethanol 200 Proof | Decon Labs | Cat #: 2716 |
Poly-D-Lysine | Thermo Fisher Scientific | Cat #: A3890401 |
Critical commercial assays | ||
NEBNext Ultra II DNA Library prep Kit | New England Biolabs | Cat #: E7645S |
NEBNext® Multiplex Oligos for Illumina® (Dual Index Primers Set 1) | New England Biolabs | Cat #: E7600S |
NextSeq 500/550 High Output v2.5 kit | Illumina | Cat #: 20024906 |
PicoPure RNA isolation kit | Applied Biosystems | Cat #: KIT0204 |
Nextera XT DNA Sample Preparation Kit | Illumina | Cat #: FC-131-1096 |
Nextera XT Index kit | Illumina | Cat #: FC-131-1002 |
NK cell isolation kit | Miltenyi | Cat #: 130-092-657 |
Myeloid Dendritic Cells Isolation kit, Human | Miltenyi | Cat #: 130-094-487 |
Seahorse Glycolysis Stress Test | Agilent | Cat #: 103020-100 |
Quantitect SYBR Green PCR kit | Qiagen | Cat #: 204145 |
Qubit 1X dsDNA HS Assay Kit | Invitrogen | Cat #: Q33231 |
High Sensitivity D1000 Reagents | Agilent Technologies | Cat #: 5067-5585 |
High Sensitivity D5000 Reagents | Agilent Technologies | Cat #: 5067-5593 |
CyQuant LDH Cytotoxicity Assay | Invitrogen | Cat #: C20301 |
Deposited data | ||
Cut&Run sequencing data | This paper | Omnibus GSE232916 |
RNA sequencing data | This paper | Omnibus GSE232916 |
Experimental models: Cell lines | ||
K562 | ATCC | CVCL_004 |
Oligonucleotides | ||
Primer: Il-15 Forward: CCGGA GATGCAAGTATTCATG |
This paper | N/A |
Primer: Il-15 Reverse: CCTCA CATTCTTTGCATCCAG |
This paper | N/A |
Primer: ACTB Forward: CTGGA ACGGTGAAGGTGACA |
This paper | N/A |
Primer: ACTB Reverse: CGGC CACATTGTGAACTTTG |
This paper | N/A |
Software and algorithms | ||
BD FACS Diva | BD Biosciences | N/A |
MACS2 | Langmead et al.67 | N/A |
DeepTools | Zhang et al.68 | N/A |
Diffbind | Ramírez et al.69 | N/A |
DESeq2 | Risso et al.70 | N/A |
Ingenuity Pathway Analysis | Qiagen | version 90348151 |
FlowJo | Tree Star LLC | version 10.5.3 |
Wave | Agilent Technologies | version 2.6.0 |
QuantStudio™ Real-Time PCR Software | Thermo Fisher Scientific | version 1.3 |
GraphPad | Prism | version 9.5.1 |
Other | ||
Biorender | https://biorender.com | N/A |
Resource availability
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Xu G. Yu (xyu@mgh.harvard.edu).
Materials availability
This study did not generate new unique reagents.
Data and code availability
-
•
The epigenomic and transcriptomic sequencing data are available in GEO and are publicly available as of the date of publication. Accession numbers are listed in the key resources table.
-
•
This paper does not report original code.
-
•
Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.
Experimental model and study participant details
HIV-1 ECs (n = 40) who had maintained undetectable levels of HIV-1 replication for a median of 5 years in the absence of antiretroviral therapy (viral load < 50 copies/mL; median CD4+ T cell count 920 cells/mm3), people living with HIV-1 treated with antiretroviral therapy (ARTs; n = 33; viral load <50 copies/mL; median CD4+ T cell count 727 cells/mm3) and people without HIV-1 (HIVNs; n = 31) were recruited for this study. The clinical and demographic characteristics of the study subjects are listed in Table S4. Additional PBMC samples from people without HIV-1 collected at the MGH Blood Bank were obtained for BCL-2 in vitro inhibition using Venetoclax experiments. All subjects gave written informed consent, and the study was approved by the IRB of Massachusetts General Hospital.
Method details
Flow cytometry NK cell sorting
PBMCs were thawed, stained with LIVE/DEAD Green Viability Dye (Invitrogen) for 15 minutes at 4°C and subsequently preincubated for 10 min with of FcR blocking reagent (Miltenyi). Afterward, cells were incubated for 25 minutes at 4°C with anti-CD3 (clone HIT3a; BioLegend), anti-CD14 (clone HCD14; BioLegend), anti-CD19 (clone HIB19; BioLegend), anti-CD56 (clone HCD56; BioLegend) and anti-CD16 (clone 3G8; BioLegend) antibodies. Cells were then sorted for CD56dim CD16+ cNK cells and CD56bright CD16- NK cells on a BD FACSAria Fusion (BD Bioscience) at the Ragon Institute Imaging Core Facility.
CUT&RUN sequencing
A standard CUT&RUN sequencing protocol was used42 with minor modifications. Briefly, sorted CD56dim CD16+ and CD56bright CD16- NK cells from ECs, ARTs and HIVNs were bound to concanavalin A–coated magnetic beads (Bangs Laboratories), followed by cell permeabilization using 0.01% digitonin (Millipore) in wash buffer. Primary antibodies against intracellular H3K27ac, H3K27me3, and H3K4me3 histone marks (Cell Signaling Technology) were added, and cells were incubated at 4°C for overnight. Guinea pig anti-rabbit IgG antibody (Antibodies-online) was used as a negative control. The next day, fusion protein CUTANA pA/G-MNase (20×) (Epicypher) was added and cells were incubated at 4°C for 1 hour, followed by chromatin digestion using 100 mM CaCl2 (Thermo Fisher Scientific). Stop buffer was then added to stop the chromatin digestion. DNA fragments were extracted using phenol chloroform (Invitrogen) and the extracted DNA was eluted in 1 mM Tris-HCl pH 8.0 (Thermo Fisher Scientific) + 0.1 mM EDTA (Sigma-Aldrich). The DNA library was prepared using NEBNext Ultra II DNA Library Prep Kit for Illumina Sequencing (New England Biolabs). The DNA library concentration and quality were measured by Qubit 1× dsDNA HS kit (Life Technologies) and D1000 High Sensitivity TapeStation (Agilent), respectively. The sequencing was performed using NextSeq 500/550 High Output v2.5 kit (75 cycles) (Illumina) on a NextSeq 500 Instrument (Illumina). Adapters and low-quality reads were trimmed using Trimmomatic71 and aligned to the human genome (GRCh38) using Bowtie2.67 Peak calling was implemented using MACS2.68 For visualization, the coverage profile was calculated using DeepTools.69 Differential binding analysis was performed using DiffBind.72 The CUT&RUN sequencing data are available in Gene Expression Omnibus GSE232916.
Gene expression analysis by bulk RNA sequencing
Total RNA from sorted CD56dim CD16+ and CD56bright CD16- NK cells, as well as from NK cells with and without IL-15, was extracted and purified using the PicoPure RNA Isolation Kit (Applied Biosystems). Subsequently, RNAseq libraries were generated as previously described.73 The whole transcriptome amplification (WTA) and tagmentation-based library preparation were performed using Nextera XT (Illumina), followed by sequencing on a NextSeq 500 Instrument (Illumina). Sequences from RNAseq were aligned to the human genome (GRCh38) using STAR74 and quantified using RSEM.75 Raw counts at gene or isoform levels were normalized using External RNA Controls Consortium spiked-in controls through RUV-seq,70 and then used for differential gene expression analysis with DESeq2.76 Transcripts per million (TPM) values were used for downstream analysis. The RNA sequencing data are available in Gene Expression Omnibus GSE232916.
Flow cytometry analysis
For surface marker staining, PBMCs were thawed, stained with LIVE/DEAD Blue Viability Dye (Invitrogen) for 15 minutes at 4°C, and subsequently preincubated for 10 min with of FcR blocking reagent (Miltenyi). Afterward, cells were incubated for 25 minutes at 4°C with combinations of antibodies directed against surface markers. Subsequently, the cells were fixed in 2% paraformaldehyde (Affymetrix) in phosphate-buffered saline (PBS) for flow cytometry analysis. Staining for intracellular markers and cytokines was done by resting thawed PBMCs for 2 hours at 37°C, 5% CO2. Cells were then co-cultured with K562 cell line or stimulated with Cell Activation Cocktail without Brefeldin A (containing PMA and ionomycin; BioLegend), in the presence of anti-CD107a antibody (clone H4A3; BD Biosciences). After 1 hour, Brefeldin A (BioLegend) and Monensin (BD Biosciences) were added, and cells were incubated for additional 4 hours. Following incubation, cells were then washed in PBS, stained with LIVE/DEAD Blue Viability Dye (Invitrogen) for 15 minutes at 4°C, and subsequently preincubated for 10 min with of FcR blocking reagent (Miltenyi). Afterward, cells were incubated for 30 minutes 4°C with combinations of antibodies directed against surface markers. Cells were then fixed and permeabilized using FOXP3/Transcription Factor Staining Buffer (Invitrogen). Next, cells were incubated for 30 minutes at 4°C with combinations of antibodies directed against intracellular markers. Flow cytometry data were acquired using BD FACSymphony (BD Biosciences) and analyzed using FlowJo v.10.5.3 software (Tree Star LLC).
Magnetic isolation of NK cells and mDCs
Total NK cells from PBMCs were isolated using NK Cell Isolation Kit, Human (Miltenyi) and LS columns by negative selection. mDCs from PBMCs were isolated using Human Myeloid Dendritic Cells Isolation Kit (Miltenyi) and LD columns by negative selection. The purity of cells after isolation was greater than 90%. The isolated NK cells and mDCs were used for downstream assays.
In vitro cell culture
Isolated NK cells or total PBMCs were cultured in medium only (negative control) or with 10 ng/mL IL-15 (Miltenyi) for 24 hours. When indicated, BCL2 inhibitor Venetoclax (Selleckchem) was added at a concentration of 100nM. Isolated mDCs were cultured in medium only (negative control) or with 2 μg/mL TLR3 ligand Poly(I:C) (Invivogen) for 24 hours. K562 were cultured in medium only for expansion. The cells were cultured in RPMI medium (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS) (MilliporeSigma), 1% l-glutamine (Corning), 1% penicillin/streptomycin (Corning), and 1% HEPES buffer (Corning) and kept at 37°C in 5% CO2 during the culture.
In vitro cytotoxicity assay
Isolated NK cells were plated at 100,000 cells/well, in 50uL of medium, with or without IL-15 supplementation (10 ng/mL), as indicated, for 1h at 37°C in 5% CO2. After 1h, K562 cells were co-cultured with NK cells, at an effector-target range of 10:1, in a final volume of 100uL, for 4h at 37°C in 5% CO2. Target cell killing was analyzed by measuring LDH concentration in the culture supernatant, using the kit CyQuant LDH Cytotoxicity Assay (Invitrogen) following the manufacturer’s instructions. Cytotoxic activities were calculated using the following formula:
Glycolysis stress test
The extracellular acidification rate (ECAR), which indicates glycolytic activities was analyzed using the Seahorse Glycolysis Stress Test (Agilent) on a Seahorse XFe96 Analyzer (Agilent) according to the manufacturer’s protocol. Briefly, conditioned NK cells were harvested, washed using prewarmed supplemented RPMI medium, and plated on XF96 cell culture microplates (Agilent) coated with poly-d-lysine (Thermo Fisher Scientific) to adhere the cells on the microplate surface. Prior to the assay, the RPMI medium was replaced with XF DMEM Medium, pH 7.4 (Agilent), supplemented with 2 mM glutamine (Agilent). At indicated time points, ECAR was measured in the basal condition and in response to 10 mM glucose, 6 mM oligomycin and 50 mM 2-DG (Agilent).
RT-PCR
mDCs were washed in 1× PBS and lysed using PicoPure Extraction Buffer (Applied Biosystems). Total RNA was extracted and purified using the PicoPure RNA Isolation Kit (Applied Biosystems), according to the manufacturer’s protocol. Next, total RNA was reverse transcribed using SuperScript IV Reverse Transcriptase (Invitrogen) into cDNA. Quantitative PCR was performed using the Quantitect SYBR Green PCR Kit (Qiagen) and primers designed to amplify IL15. A ViiA7 instrument (Life Technologies) was used. ACTB was analyzed as a housekeeping gene. The expression of IL15 relative to the negative control was calculated using the Livak (2(–ΔΔCt)) method.
Quantification and statistical analysis
Differences between 2 groups were tested for statistical significance using unpaired, 2-tailed t test or Mann Whitney test (unpaired observations) and paired, 2-tailed t test or Wilcoxon matched pairs signed rank test (paired observations). Differences among 3 groups or more were tested using 1-way ANOVA or Kruskal-Wallis (unpaired observations) and repeated measures ANOVA or Friedman test (paired observations). Correlation between 2 variables was tested using Spearman or Pearson test. Normality distribution was tested using Kolmogorov Smirnov test.
Acknowledgments
X.G.Y. is supported by NIH grants AI155171, AI116228, AI078799, HL134539, and DA047034; amfAR ARCHE grant no. 110393-72-RPRL; and the Bill and Melinda Gates Foundation (INV-002703). M. Lichterfeld is supported by NIH grants AI117841, AI120008, AI130005, DK120387, AI152979, AI155233, AI135940, and AI169768; the American Foundation for AIDS Research (amfAR, no. 110181-69-RGCV); and the Campbell Foundation. M. Lichterfeld and X.G.Y. are members of the DARE, ERASE, PAVE, and BEAT-HIV Martin Delaney Collaboratories (UM1 AI164560, AI164562, AI164566, and AI164570).
Author contributions
Concept, design, and discussion, C.A.H., M. Lichterfeld, and X.G.Y.; laboratory investigation, C.A.H., M. Lancien, and Y.R.; bioinformatics analysis, C.G.; data interpretation, analysis, and presentation, C.A.H., M. Lancien. C.G., M. Lichterfeld, and X.G.Y.; supervision, M. Lichterfeld and X.G.Y.; manuscript writing, review, and editing, C.A.H., M. Lancien, M. Lichterfeld, and X.G.Y.
Declaration of interests
The authors declare no competing interests.
Inclusion and diversity
One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in their field of research or within their geographical location. One or more of the authors of this paper self-identifies as a member of the LGBTQIA+ community.
Published: December 3, 2023
Footnotes
Supplemental information can be found online at https://doi.org/10.1016/j.celrep.2023.113530.
Supplemental information
References
- 1.Jensen B.E.O., Knops E., Cords L., Lübke N., Salgado M., Busman-Sahay K., Estes J.D., Huyveneers L.E.P., Perdomo-Celis F., Wittner M., et al. In-depth virological and immunological characterization of HIV-1 cure after CCR5Delta32/Delta32 allogeneic hematopoietic stem cell transplantation. Nat. Med. 2023;29:583–587. doi: 10.1038/s41591-023-02213-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Hsu J., Van Besien K., Glesby M.J., Pahwa S., Coletti A., Warshaw M.G., Petz L., Moore T.B., Chen Y.H., Pallikkuth S., et al. HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell. 2023;186:1115–1126.e8. doi: 10.1016/j.cell.2023.02.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Gupta R.K., Abdul-Jawad S., McCoy L.E., Mok H.P., Peppa D., Salgado M., Martinez-Picado J., Nijhuis M., Wensing A.M.J., Lee H., et al. HIV-1 remission following CCR5Delta32/Delta32 haematopoietic stem-cell transplantation. Nature. 2019;568:244–248. doi: 10.1038/s41586-019-1027-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Hütter G., Nowak D., Mossner M., Ganepola S., Müssig A., Allers K., Schneider T., Hofmann J., Kücherer C., Blau O., et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 2009;360:692–698. doi: 10.1056/NEJMoa0802905. [DOI] [PubMed] [Google Scholar]
- 5.Jiang C., Lian X., Gao C., Sun X., Einkauf K.B., Chevalier J.M., Chen S.M.Y., Hua S., Rhee B., Chang K., et al. Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature. 2020;585:261–267. doi: 10.1038/s41586-020-2651-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Turk G., Seiger K., Lian X., Sun W., Parsons E.M., Gao C., Rassadkina Y., Polo M.L., Czernikier A., Ghiglione Y., et al. A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation. Ann. Intern. Med. 2022;175:95–100. doi: 10.7326/L21-0297. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Yang O.O., Cumberland W.G., Escobar R., Liao D., Chew K.W. Demographics and natural history of HIV-1-infected spontaneous controllers of viremia. AIDS. 2017;31:1091–1098. doi: 10.1097/QAD.0000000000001443. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Lian X., Gao C., Sun X., Jiang C., Einkauf K.B., Seiger K.W., Chevalier J.M., Yuki Y., Martin M., Hoh R., et al. Signatures of immune selection in intact and defective proviruses distinguish HIV-1 elite controllers. Sci. Transl. Med. 2021;13 doi: 10.1126/scitranslmed.abl4097. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Hartana C.A., Yu X.G. Immunological effector mechanisms in HIV-1 elite controllers. Curr. Opin. HIV AIDS. 2021;16:243–248. doi: 10.1097/COH.0000000000000693. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.International HIV Controllers Study. Pereyra F., Jia X., McLaren P.J., Telenti A., de Bakker P.I.W., Walker B.D., Ripke S., Brumme C.J., Pulit S.L., et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010;330:1551–1557. doi: 10.1126/science.1195271. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Gaiha G.D., Rossin E.J., Urbach J., Landeros C., Collins D.R., Nwonu C., Muzhingi I., Anahtar M.N., Waring O.M., Piechocka-Trocha A., et al. Structural topology defines protective CD8+ T cell epitopes in the HIV proteome. Science. 2019;364:480–484. doi: 10.1126/science.aav5095. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Monel B., McKeon A., Lamothe-Molina P., Jani P., Boucau J., Pacheco Y., Jones R.B., Le Gall S., Walker B.D. HIV Controllers Exhibit Effective CD8+ T Cell Recognition of HIV-1-Infected Non-activated CD4+ T Cells. Cell Rep. 2019;27:142–153.e4. doi: 10.1016/j.celrep.2019.03.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Angin M., Volant S., Passaes C., Lecuroux C., Monceaux V., Dillies M.-A., Valle Casuso J.C., Pancino G., Vaslin B., Le Grand R., et al. Metabolic plasticity of HIV-specific CD8+ T cells is associated with enhanced antiviral potential and natural control of HIV-1 infection. Nat. Metab. 2019;1:704–716. doi: 10.1038/s42255-019-0081-4. [DOI] [PubMed] [Google Scholar]
- 14.Collins D.R., Gaiha G.D., Walker B.D. CD8(+) T cells in HIV control, cure and prevention. Nat. Rev. Immunol. 2020;20:471–482. doi: 10.1038/s41577-020-0274-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Board N.L., Moskovljevic M., Wu F., Siliciano R.F., Siliciano J.D. Engaging innate immunity in HIV-1 cure strategies. Nat. Rev. Immunol. 2022;22:499–512. doi: 10.1038/s41577-021-00649-1. [DOI] [PubMed] [Google Scholar]
- 16.Sciumè G., Mikami Y., Jankovic D., Nagashima H., Villarino A.V., Morrison T., Yao C., Signorella S., Sun H.W., Brooks S.R., et al. Rapid Enhancer Remodeling and Transcription Factor Repurposing Enable High Magnitude Gene Induction upon Acute Activation of NK Cells. Immunity. 2020;53:745–758.e4. doi: 10.1016/j.immuni.2020.09.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Lau C.M., Adams N.M., Geary C.D., Weizman O.E., Rapp M., Pritykin Y., Leslie C.S., Sun J.C. Epigenetic control of innate and adaptive immune memory. Nat. Immunol. 2018;19:963–972. doi: 10.1038/s41590-018-0176-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Stary V., Pandey R.V., Strobl J., Kleissl L., Starlinger P., Pereyra D., Weninger W., Fischer G.F., Bock C., Farlik M., Stary G. A discrete subset of epigenetically primed human NK cells mediates antigen-specific immune responses. Sci. Immunol. 2020;5 doi: 10.1126/sciimmunol.aba6232. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat. Immunol. 2008;9:503–510. doi: 10.1038/ni1582. [DOI] [PubMed] [Google Scholar]
- 20.Poli A., Michel T., Thérésine M., Andrès E., Hentges F., Zimmer J. CD56 bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126:458–465. doi: 10.1111/j.1365-2567.2008.03027.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Horowitz A., Strauss-Albee D.M., Leipold M., Kubo J., Nemat-Gorgani N., Dogan O.C., Dekker C.L., Mackey S., Maecker H., Swan G.E., et al. Genetic and Environmental Determinants of Human NK Cell Diversity Revealed by Mass Cytometry. Sci. Transl. Med. 2013;5:208ra145. doi: 10.1126/scitranslmed.3006702. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Dominguez-Molina B., Ferrando-Martinez S., Tarancon-Diez L., Hernandez-Quero J., Genebat M., Vidal F., Muñoz-Fernandez M.A., Leal M., Koup R., Ruiz-Mateos E. Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance—Supercontrollers. Front. Immunol. 2018;9:2897. doi: 10.3389/fimmu.2018.02897. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Pohlmeyer C.W., Gonzalez V.D., Irrinki A., Ramirez R.N., Li L., Mulato A., Murry J.P., Arvey A., Hoh R., Deeks S.G., et al. Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control. J. Virol. 2019;93:e01790-18. doi: 10.1128/JVI.01790-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.O'Connell K.A., Han Y., Williams T.M., Siliciano R.F., Blankson J.N. Role of natural killer cells in a cohort of elite suppressors: low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus type 1 replication in vitro. J. Virol. 2009;83:5028–5034. doi: 10.1128/JVI.02551-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Tomescu C., Duh F.M., Hoh R., Viviani A., Harvill K., Martin M.P., carrington M., Deeks S.G., Montaner L.J. Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers. AIDS. 2012;26:1869–1878. doi: 10.1097/QAD.0b013e32835861b0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Marras F., Nicco E., Bozzano F., Di Biagio A., Dentone C., Pontali E., Boni S., Setti M., Orofino G., Mantia E., et al. Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation. Proc. Natl. Acad. Sci. USA. 2013;110:11970–11975. doi: 10.1073/pnas.1302090110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Walker-Sperling V.E., Pohlmeyer C.W., Veenhuis R.T., May M., Luna K.A., Kirkpatrick A.R., Laeyendecker o., Cox A.L., carrington M., Bailey J.R., et al. Factors Associated With the Control of Viral Replication and Virologic Breakthrough in a Recently Infected HIV-1 Controller. EBioMedicine. 2017;16:141–149. doi: 10.1016/j.ebiom.2017.01.034. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Fisher L., Zinter M., Stanfield-Oakley S., Carpp L.N., Edwards R.W., Denny T., Moodie Z., Laher F., Bekker L.G., McElrath M.J., et al. Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. Front. Immunol. 2019;10:2741. doi: 10.3389/fimmu.2019.02741. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Garrido C., Abad-Fernandez M., Tuyishime M., Pollara J.J., Ferrari G., Soriano-Sarabia N., Margolis D.M. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo. J. Virol. 2018;92:e00235-18. doi: 10.1128/JVI.00235-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.May M.E., Pohlmeyer C.W., Kwaa A.K., Mankowski M.C., Bailey J.R., Blankson J.N. Combined Effects of HLA-B∗57/5801 Elite Suppressor CD8+ T Cells and NK Cells on HIV-1 Replication. Front. Cell. Infect. Microbiol. 2020;10:113. doi: 10.3389/fcimb.2020.00113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Climent N., Ambrosioni J., González T., Xufré C., Casadellà M., Noguera-Julian M., Paredes R., Plana M., Grau-Expósito J., Mallolas J., et al. Immunological and virological findings in a patient with exceptional post-treatment control: a case report. Lancet. HIV. 2023;10:e42–e51. doi: 10.1016/S2352-3018(22)00302-2. [DOI] [PubMed] [Google Scholar]
- 32.Paust S., Gill H.S., Wang B.Z., Flynn M.P., Moseman E.A., Senman B., Szczepanik M., Telenti A., Askenase P.W., Compans R.W., von Andrian U.H. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat. Immunol. 2010;11:1127–1135. doi: 10.1038/ni.1953. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Gillard G.O., Bivas-Benita M., Hovav A.H., Grandpre L.E., Panas M.W., Seaman M.S., Haynes B.F., Letvin N.L. Thy1+ NK [corrected] cells from vaccinia virus-primed mice confer protection against vaccinia virus challenge in the absence of adaptive lymphocytes. PLoS Pathog. 2011;7 doi: 10.1371/journal.ppat.1002141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Habib S., El Andaloussi A., Hisham A., Ismail N. NK Cell-Mediated Regulation of Protective Memory Responses against Intracellular Ehrlichial Pathogens. PLoS One. 2016;11 doi: 10.1371/journal.pone.0153223. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Reeves R.K., Li H., Jost S., Blass E., Li H., Schafer J.L., Varner V., Manickam C., Eslamizar L., Altfeld M., et al. Antigen-specific NK cell memory in rhesus macaques. Nat. Immunol. 2015;16:927–932. doi: 10.1038/ni.3227. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Netea M.G., Joosten L.A.B., Latz E., Mills K.H.G., Natoli G., Stunnenberg H.G., O'Neill L.A.J., Xavier R.J. Trained immunity: A program of innate immune memory in health and disease. Science. 2016;352:aaf1098. doi: 10.1126/science.aaf1098. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Netea M.G., Giamarellos-Bourboulis E.J., Domínguez-Andrés J., Curtis N., van Crevel R., van de Veerdonk F.L., Bonten M. Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection. Cell. 2020;181:969–977. doi: 10.1016/j.cell.2020.04.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Netea M.G., Domínguez-Andrés J., Barreiro L.B., Chavakis T., Divangahi M., Fuchs E., Joosten L.A.B., van der Meer J.W.M., Mhlanga M.M., Mulder W.J.M., et al. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 2020;20:375–388. doi: 10.1038/s41577-020-0285-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Arts R.J.W., Joosten L.A.B., Netea M.G. Immunometabolic circuits in trained immunity. Semin. Immunol. 2016;28:425–430. doi: 10.1016/j.smim.2016.09.002. [DOI] [PubMed] [Google Scholar]
- 40.Arts R.J.W., Moorlag S.J.C.F.M., Novakovic B., Li Y., Wang S.-Y., Oosting M., Kumar V., Xavier R.J., Wijmenga C., Joosten L.A.B., et al. BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity. Cell Host Microbe. 2018;23:89–100.e5. doi: 10.1016/j.chom.2017.12.010. [DOI] [PubMed] [Google Scholar]
- 41.Hartana C.A., Rassadkina Y., Gao C., Martin-Gayo E., Walker B.D., Lichterfeld M., Yu X.G. Long noncoding RNA MIR4435-2HG enhances metabolic function of myeloid dendritic cells from HIV-1 elite controllers. J. Clin. Invest. 2021;131 doi: 10.1172/JCI146136. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Skene P.J., Henikoff J.G., Henikoff S. Targeted in situ genome-wide profiling with high efficiency for low cell numbers. Nat. Protoc. 2018;13:1006–1019. doi: 10.1038/nprot.2018.015. [DOI] [PubMed] [Google Scholar]
- 43.Leonard W.J., Lin J.X., O'Shea J.J. The gammac Family of Cytokines: Basic Biology to Therapeutic Ramifications. Immunity. 2019;50:832–850. doi: 10.1016/j.immuni.2019.03.028. [DOI] [PubMed] [Google Scholar]
- 44.Abel A.M., Yang C., Thakar M.S., Malarkannan S. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front. Immunol. 2018;9:1869. doi: 10.3389/fimmu.2018.01869. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Wu Y., Tian Z., Wei H. Developmental and Functional Control of Natural Killer Cells by Cytokines. Front. Immunol. 2017;8:930. doi: 10.3389/fimmu.2017.00930. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Ferlazzo G., Morandi B. Cross-Talks between Natural Killer Cells and Distinct Subsets of Dendritic Cells. Front. Immunol. 2014;5:159. doi: 10.3389/fimmu.2014.00159. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Cooper M.A., Fehniger T.A., Fuchs A., Colonna M., Caligiuri M.A. NK cell and DC interactions. Trends Immunol. 2004;25:47–52. doi: 10.1016/j.it.2003.10.012. [DOI] [PubMed] [Google Scholar]
- 48.Martin-Gayo E., Gao C., Chen H.R., Ouyang Z., Kim D., Kolb K.E., Shalek A.K., Walker B.D., Lichterfeld M., Yu X.G. Immunological Fingerprints of Controllers Developing Neutralizing HIV-1 Antibodies. Cell Rep. 2020;30:984–996.e4. doi: 10.1016/j.celrep.2019.12.087. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Fok E.T., Davignon L., Fanucchi S., Mhlanga M.M. The lncRNA Connection Between Cellular Metabolism and Epigenetics in Trained Immunity. Front. Immunol. 2018;9:3184. doi: 10.3389/fimmu.2018.03184. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Previte D.M., Martins C.P., O’Connor E.C., Marre M.L., Coudriet G.M., Beck N.W., Menk A.V., Wright R.H., Tse H.M., Delgoffe G.M., Piganelli J.D. Lymphocyte Activation Gene-3 Maintains Mitochondrial and Metabolic Quiescence in Naive CD4+ T Cells. Cell Rep. 2019;27:129–141.e4. doi: 10.1016/j.celrep.2019.03.004. [DOI] [PubMed] [Google Scholar]
- 51.Díez-Fuertes F., De La Torre-Tarazona H.E., Calonge E., Pernas M., Alonso-Socas M.D.M., Capa L., García-Pérez J., Sakuntabhai A., Alcamí J. Transcriptome Sequencing of Peripheral Blood Mononuclear Cells from Elite Controller-Long Term Non Progressors. Sci. Rep. 2019;9 doi: 10.1038/s41598-019-50642-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Wang S., Zhang Q., Hui H., Agrawal K., Karris M.A.Y., Rana T.M. An atlas of immune cell exhaustion in HIV-infected individuals revealed by single-cell transcriptomics. Emerg. Microbes Infect. 2020;9:2333–2347. doi: 10.1080/22221751.2020.1826361. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Wang X.M., Zhang J.Y., Xing X., Huang H.H., Xia P., Dai X.P., Hu W., Zhang C., Song J.-W., Fan X., et al. Global transcriptomic characterization of T cells in individuals with chronic HIV-1 infection. Cell Discov. 2022;8:29. doi: 10.1038/s41421-021-00367-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Pollara J., Khanal S., Edwards R.W., Hora B., Ferrari G., Haynes B.F., Bradley T. Single-cell analysis of immune cell transcriptome during HIV-1 infection and therapy. BMC Immunol. 2022;23:48. doi: 10.1186/s12865-022-00523-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Cavalli G., Tengesdal I.W., Gresnigt M., Nemkov T., Arts R.J.W., Domínguez-Andrés J., Molteni R., Stefanoni D., Cantoni E., Cassina L., et al. The anti-inflammatory cytokine interleukin-37 is an inhibitor of trainedimmunity. Cell Rep. 2021;35 doi: 10.1016/j.celrep.2021.108955. [DOI] [PubMed] [Google Scholar]
- 56.Miller J.S., Davis Z.B., Helgeson E., Reilly C., Thorkelson A., Anderson J., Lima N.S., Jorstad S., Hart G.T., Lee J.H., et al. Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial. Nat. Med. 2022;28:392–400. doi: 10.1038/s41591-021-01651-9. [DOI] [PubMed] [Google Scholar]
- 57.Webb G.M., Molden J., Busman-Sahay K., Abdulhaqq S., Wu H.L., Weber W.C., Bateman K.B., Reed J.S., Northrup M., Maier N., et al. The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. PLoS Pathog. 2020;16 doi: 10.1371/journal.ppat.1008339. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Okoye A.A., DeGottardi M.Q., Fukazawa Y., Vaidya M., Abana C.O., Konfe A.L., Fachko D.N., Duell D.M., Li H., Lum R., et al. Role of IL-15 Signaling in the Pathogenesis of Simian Immunodeficiency Virus Infection in Rhesus Macaques. J. Immunol. 2019;203:2928–2943. doi: 10.4049/jimmunol.1900792. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Malouli D., Gilbride R.M., Wu H.L., Hwang J.M., Maier N., Hughes C.M., Newhouse D., Morrow D., Ventura A.B., Law L., et al. Cytomegalovirus-vaccine-induced unconventional T cell priming and control of SIV replication is conserved between primate species. Cell Host Microbe. 2022;30:1207–1218.e7. doi: 10.1016/j.chom.2022.07.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Han K.P., Zhu X., Liu B., Jeng E., Kong L., Yovandich J.L., Vyas V.V., Marcus W.D., Chavaillaz P.-A., Romero C.A., et al. IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine. 2011;56:804–810. doi: 10.1016/j.cyto.2011.09.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Sivori S., Della Chiesa M., Carlomagno S., Quatrini L., Munari E., Vacca P., Tumino N., Mariotti F.R., Mingari M.C., Pende D., Moretta L. Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer. Front. Immunol. 2020;11:2156. doi: 10.3389/fimmu.2020.02156. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Sivori S., Vacca P., Del Zotto G., Munari E., Mingari M.C., Moretta L. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell. Mol. Immunol. 2019;16:430–441. doi: 10.1038/s41423-019-0206-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Horowitz A., Djaoud Z., Nemat-Gorgani N., Blokhuis J., Hilton H.G., Béziat V., Malmberg K.-J., Norman P.J., Guethlein L.A., Parham P. Class I HLA haplotypes form two schools that educate NK cells in different ways. Sci. Immunol. 2016;1 doi: 10.1126/sciimmunol.aag1672. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Anfossi N., André P., Guia S., Falk C.S., Roetynck S., Stewart C.A., Breso V., Frassati C., Reviron D., Middleton D., et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006;25:331–342. doi: 10.1016/j.immuni.2006.06.013. [DOI] [PubMed] [Google Scholar]
- 65.Sun W., Gao C., Hartana C.A., Osborn M.R., Einkauf K.B., Lian X., Bone B., Bonheur N., Chun T.-W., Rosenberg E.S., et al. Phenotypic signatures of immune selection in HIV-1 reservoir cells. Nature. 2023;614:309–317. doi: 10.1038/s41586-022-05538-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Hartana C.A., Rassadkina Y., Gao C., Martin-Gayo E., Walker B.D., Lichterfeld M., Yu X.G. Long noncoding RNA MIR4435-2HG enhances metabolic function of myeloid dendritic cells from HIV-1 elite controllers. J. Clin. Invest. 2021;131 doi: 10.1172/JCI146136. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Langmead B., Salzberg S.L. Fast gapped-read alignment with Bowtie 2. Nat. Methods. 2012;9:357–359. doi: 10.1038/nmeth.1923. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Zhang Y., Liu T., Meyer C.A., Eeckhoute J., Johnson D.S., Bernstein B.E., Nusbaum C., Myers R.M., Brown M., Li W., Liu X.S. Model-based Analysis of ChIP-Seq (MACS) Genome Biol. 2008;9:R137. doi: 10.1186/gb-2008-9-9-r137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Ramírez F., Ryan D.P., Grüning B., Bhardwaj V., Kilpert F., Richter A.S., Heyne S., Dündar F., Manke T. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 2016;44:W160–W165. doi: 10.1093/nar/gkw257. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Risso D., Ngai J., Speed T.P., Dudoit S. Normalization of RNA-seq data using factor analysis of control genes or samples. Nat. Biotechnol. 2014;32:896–902. doi: 10.1038/nbt.2931. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Bolger A.M., Lohse M., Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–2120. doi: 10.1093/bioinformatics/btu170. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Ross-Innes C.S., Stark R., Teschendorff A.E., Holmes K.A., Ali H.R., Dunning M.J., Brown G.D., Gojis O., Ellis I.O., Green A.R., et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature. 2012;481:389–393. doi: 10.1038/nature10730. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Trombetta J.J., Gennert D., Lu D., Satija R., Shalek A.K., Regev A. Preparation of Single-Cell RNA-Seq Libraries for Next Generation Sequencing. Curr. Protoc. Mol. Biol. 2014;107:4.22.1–4.22.17. doi: 10.1002/0471142727.mb0422s107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Dobin A., Davis C.A., Schlesinger F., Drenkow J., Zaleski C., Jha S., Batut P., Chaisson M., Gingeras T.R. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21. doi: 10.1093/bioinformatics/bts635. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Li B., Dewey C.N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinf. 2011;12:323. doi: 10.1186/1471-2105-12-323. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Love M.I., Huber W., Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
-
•
The epigenomic and transcriptomic sequencing data are available in GEO and are publicly available as of the date of publication. Accession numbers are listed in the key resources table.
-
•
This paper does not report original code.
-
•
Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.